AEON regains NYSE American compliance after July offering

AEON Biopharma, Inc. (NYSE American: AEON) said on August 3, 2026 that it had received written notice from NYSE American LLC confirming that it regained compliance with the exchange's continued listing standards relating to stockholders' equity. A letter from NYSE Regulation confirmed that AEON had resolved the previously identified deficiencies under Sections 1003(a)(i) and 1003(a)(ii) of the NYSE American Company Guide. The company expects the below-compliance indicator, shown as .BC, to be removed from the trading symbol for its Class A common stock, and expects to be removed from the exchange's list of noncompliant issuers.

What resolved the deficiency

AEON said it regained compliance after completing its underwritten public offering. The offering closed on July 15, 2026, with 17,851,599 shares of Common Stock and pre-funded warrants to purchase 24,837,008 shares of Common Stock. Each share or pre-funded warrant came with a two-year milestone warrant and a five-year milestone warrant, each to purchase one share of Common Stock. On July 23, 2026, the company sold an additional 4,696,102 shares after a partial exercise of the underwriters' over-allotment option.

The company received aggregate net proceeds of approximately $13.6 million, after underwriting discounts, commissions and estimated offering expenses. It could receive up to an additional $34.0 million in gross proceeds if the milestone warrants are exercised for cash in full. AEON believes it now has stockholders' equity above the $4.0 million minimum under Section 1003(a)(ii) of the Company Guide. The release does not name the underwriters.

A fix that rests on one offering

Because the offering closed after the end of the second fiscal quarter, the unaudited balance sheet as of June 30, 2026, to be included in the Quarterly Report on Form 10-Q, will reflect a stockholders' deficit. It will not give effect to the net proceeds of the offering, which will be reflected as a subsequent event. The company says it will remain subject to NYSE American's standard listing monitoring procedures and remains committed to maintaining strong financial discipline and governance. In plain terms, the listing was repaired by selling stock, not by the business earning money: the company lost $39.2 million in 2025, its balance sheet showed a deficit before the offering, and the compliance regained is tied to equity staying above the $4.0 million minimum. The offering also added a large number of shares and warrants, so existing holders were diluted, and each unit carried two milestone warrants that could add more shares.

Company background

AEON is a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX for therapeutic use, with the goal of full-label U.S. market entry. The release says the U.S. therapeutic neurotoxin market exceeds $3.0 billion annually. ABP-450 is the same botulinum toxin complex currently approved and marketed for cosmetic indications by Evolus, Inc. under the name Jeuveau, and Daewoong Pharmaceutical manufactures it in a facility authorized by the FDA, Health Canada and the European Medicines Agency. The product is approved as a biosimilar in India, Mexico and the Philippines. The company's lead asset is ABP-450 for debilitating medical conditions. The annual report says the company met the FDA for an initial meeting in the third quarter of 2024, commenced analytical studies in the fourth quarter of 2024, and plans to complete the majority of its analytical comparability program in 2026. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom and certain other international territories.

According to the annual report, AEON's common stock was listed on the NYSE American under the symbol AEON and began trading on July 24, 2023, after a business combination with Priveterra Acquisition Corp. For 2025, research and development expense was $4.1 million and the net loss was $39.2 million. The release is on the SEC website.

Report an error

Companies in this story

AEONAEON Biopharma, Inc.AMEX · United StatesOpen the starter desk